Recent Trials Apogee Therapeutics has launched a first-in-human clinical trial for APG990, a promising treatment for atopic dermatitis, signaling potential partnerships with healthcare providers and pharmaceutical companies interested in innovative therapies.
Strategic Investments Recent investments from Jennison Associates LLC, China Universal Asset Management Co. Ltd., and Adage Capital Partners GP L.L.C. illustrate confidence in Apogee Therapeutics' growth trajectory, presenting an opportunity for strategic collaborations or joint ventures.
Experienced Leadership With the appointment of Jeff S. Hartness as Chief Commercial Officer and Lisa Bollinger to its board of directors, Apogee Therapeutics demonstrates a strong leadership team, which can be leveraged to expand market reach through established industry connections.
Public Listing Having gone public in May 2023 and raised $345 million in IPO funds, Apogee Therapeutics is well-positioned to engage with investors, potentially attracting interest from institutional funds and high net-worth individuals seeking biotechnology opportunities.
Competitive Landscape In a market with similar biotechnology companies like Casma Therapeutics, Boundless Bio, and Generation Bio, Apogee Therapeutics' revenue range and focus on immunological therapies present opportunities for differentiation and collaboration within the competitive landscape.
18
$10M
85$10M$50M
77$10M$50M
11$10M
114$10M$50M
51
29
139$10M$50M
177$10M$50M
11$10M
40$10M
51$10M$50MApogee Therapeutics uses 8 technology products and services including SAS, Typekit, DocuSign, and more. Explore Apogee Therapeutics's tech stack below.
| Apogee Therapeutics Email Formats | Percentage |
| First.Last@apogeetherapeutics.com | 50% |
| First.Last@apogeetherapeutics.com | 50% |
Biotechnology ResearchUS, United States51-200 Employees
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.
Company Overview
Media & News
Funding & FinancialsApogee Therapeutics has raised a total of $483M of funding over 3 rounds. Their latest funding round was raised on Mar 07, 2024 in the amount of $483M.
Apogee Therapeutics's revenue is in the range of $10M$50M
Funding & FinancialsApogee Therapeutics has raised a total of $483M of funding over 3 rounds. Their latest funding round was raised on Mar 07, 2024 in the amount of $483M.
Apogee Therapeutics's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com